Alector
Update in progressALEC (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Alector, Inc. is a clinical-stage biotechnology company focused on therapies to slow neurodegeneration in the United States. Its pipeline includes Nivisnebart, a human monoclonal antibody; AL137, an anti-amyloid beta antibody in preclinical development for Alzheimer's; and AL050, a GCase enzyme replacement therapy in preclinical development for Parkinson’s and Lewy body dementia in GBA1 mutation patients. It also advances AL064 (tau siRNA), ADP062-ABC (alpha-synuclein siRNA), and ADP065-ABC (NLRP3 siRNA). A collaboration with GlaxoSmithKline targets progranulin-elevating antibodies. Founded 2013, based in South San Francisco.
Company score
- Sentiment
- -0.39
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.35
- Governance
- -0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
No news articles are available for this company yet.
Unable to load company news.
You're all caught up!